

PRESS RELEASE

April 20, 2026

CR10049, the first intra-articular OA-targeted kinase inhibitor for the treatment of the inflammatory osteoarthritis (OA) phenotype, new preclinical data presented at the OARSI World Congress on OA

Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that new exciting preclinical data supporting the advancement of CR10049 (a targeted kinase inhibitor for the inflammatory OA phenotype) will be presented at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, to be held April 23 – 26, 2026 in West Palm Beach, Florida.

Presentation Details

Title: CR10049, a long-acting symptom- and disease-modifying putative drug for the inflammatory osteoarthritis phenotype.

Abstract and Poster Number: 428

Presenting Author: Tiziana Piepoli

Presentation Session Date and Time: Friday, April 24, and Saturday, April 25, 2026, 4:15 – 5:00 pm

The abstract and data presented at the congress will be available to view in this website page following publication in the Osteoarthritis and Cartilage journal.

CR10049 (targeted kinase inhibitor for the inflammatory OA phenotype)

CR10049 is the lead of a series of small molecules with potent activity on undisclosed selected kinases that play a role in both OA pain (symptom-modifying) and inflammatory joint degeneration (structure-modifying). One such drug would be a major breakthrough in the treatment of the inflammatory OA phenotype.

Rottapharm Biotech

Rottapharm Biotech is a research company dedicated to the discovery and development of innovative drugs. It is located in Monza (Italy). The company expertise in research and development includes medicinal/computational chemistry for small molecules, development of biologics and advanced therapies, new targets validation, pharmacological and pharmacokinetic characterization of new drug candidates, original formulations, and design of

innovative clinical trials. The company strategy is to develop its own pipeline independently and then seek partnerships with pharmaceutical companies, as well as investing in alliances on innovative projects of other biotech companies or university spin-offs.

Contact

Federica Girolami, Business Development Director

Tel. +39 346 4131428

federica.girolami@rottapharmbiotech.com